{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=95",
    "query": {
      "intervention": "combined treatment",
      "page": 95
    },
    "page_size": 10
  },
  "pagination": {
    "page": 95,
    "page_size": 10,
    "total_count": 14006,
    "total_pages": 1401,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=96&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=combined+treatment&page=94&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T08:55:07.626Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04762979",
      "title": "Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Carcinoma",
        "HER2-negative Breast Cancer",
        "PIK3CA Mutant Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Aromatase inhibitor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Marina N Sharifi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2021-02-12",
      "completion_date": "2026-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 4,
      "location_summary": "Chicago, Illinois • Omaha, Nebraska • Hershey, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04762979"
    },
    {
      "nct_id": "NCT06111482",
      "title": "Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Dermatologic Conditions"
      ],
      "interventions": [
        {
          "name": "Intense pulsed light.",
          "type": "DEVICE"
        },
        {
          "name": "Radiofrequency microneedling device",
          "type": "DEVICE"
        },
        {
          "name": "Radiofrequency device",
          "type": "DEVICE"
        },
        {
          "name": "Combined energy devices",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Cynosure, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2023-09-28",
      "completion_date": "2025-02",
      "has_results": false,
      "last_update_posted_date": "2023-11-01",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 1,
      "location_summary": "Westford, Massachusetts",
      "locations": [
        {
          "city": "Westford",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06111482"
    },
    {
      "nct_id": "NCT02270788",
      "title": "Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Crenolanib",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "methotrexate, hydrocortisone and cytarabine with leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 10,
      "start_date": "2015-04-02",
      "completion_date": "2016-10-17",
      "has_results": false,
      "last_update_posted_date": "2017-10-03",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02270788"
    },
    {
      "nct_id": "NCT01338883",
      "title": "Efficacy, Safety, and Tolerability of Cenicriviroc (CVC) in Combination With Truvada or Sustiva Plus Truvada in HIV 1-infected, Antiretroviral Treatment-naïve, Adult Patients Infected With Only CCR5-tropic Virus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV-1 Infection"
      ],
      "interventions": [
        {
          "name": "Cenicriviroc 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Cenicriviroc 200 mg + Truvada",
          "type": "DRUG"
        },
        {
          "name": "Sustiva + Truvada",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tobira Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2011-06",
      "completion_date": "2013-06",
      "has_results": false,
      "last_update_posted_date": "2013-07-10",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01338883"
    },
    {
      "nct_id": "NCT00302159",
      "title": "Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Gliomas",
        "Brain Tumors"
      ],
      "interventions": [
        {
          "name": "adjuvant therapy",
          "type": "PROCEDURE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        },
        {
          "name": "Radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2006-03",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2016-08-18",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 3,
      "location_summary": "Bethesda, Maryland • Philadelphia, Pennsylvania • Richmond, Virginia",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00302159"
    },
    {
      "nct_id": "NCT06027580",
      "title": "Orthosis to Improve Trunk Control in Infants Age 6-18 Months",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cerebral Palsy"
      ],
      "interventions": [
        {
          "name": "SPIO® Core-MAX® Expedition thoracolumbosacral orthosis",
          "type": "DEVICE"
        },
        {
          "name": "Standard Care Therapy option",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "OTHER"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Months",
        "sex": "ALL",
        "summary": "6 Months to 18 Months"
      },
      "enrollment_count": 21,
      "start_date": "2026-08-06",
      "completion_date": "2026-08-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06027580"
    },
    {
      "nct_id": "NCT02083679",
      "title": "Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2014-07",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2016-10-25",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02083679"
    },
    {
      "nct_id": "NCT00336479",
      "title": "Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon Alfa 2a",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 263,
      "start_date": "2006-06",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 36,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Palo Alto, California + 28 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00336479"
    },
    {
      "nct_id": "NCT00002796",
      "title": "Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mucinous Adenocarcinoma of the Colon",
        "Mucinous Adenocarcinoma of the Rectum",
        "Recurrent Colon Cancer",
        "Recurrent Rectal Cancer",
        "Signet Ring Adenocarcinoma of the Colon",
        "Signet Ring Adenocarcinoma of the Rectum",
        "Stage IVA Colon Cancer",
        "Stage IVA Rectal Cancer",
        "Stage IVB Colon Cancer",
        "Stage IVB Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "sodium phenylbutyrate",
          "type": "DRUG"
        },
        {
          "name": "indomethacin",
          "type": "DRUG"
        },
        {
          "name": "recombinant interferon gamma",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 46,
      "start_date": "1997-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-01",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002796"
    },
    {
      "nct_id": "NCT01495988",
      "title": "Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Metastatic Melanoma"
      ],
      "interventions": [
        {
          "name": "Vemurafenib",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cobimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melanoma Research Foundation Breakthrough Consortium",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2013-08",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-10-24",
      "last_synced_at": "2026-11-15T08:55:07.626Z",
      "location_count": 14,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01495988"
    }
  ]
}